 |
|
International scientists tackle obstacles to treating brain disorders
December 21, 2007U of M and OHSU researchers call for more studies and resources to solve drug delivery problems
A research team led by scientists at the University of Minnesota Medical School and Oregon Health & Science University have outlined the challenges and made suggestions on how to advance research and improve treatments for brain disorders.
The review article is published in the January 2008 issue of the Lancet Neurology and will be available online on December 17.
Many neurological disorders are difficult to treat because of a natural barrier in the brain. The blood-brain barrier is a specialized system of cells that acts as a gatekeeper for the brain, blocking harmful substances from entering while allowing in necessary nutrients. The barrier is necessary to keep the brain and nervous system healthy. However, it also causes problems in medication delivery because it treats medications as the enemy, preventing the therapeutic agents from doing their job.
"In order to develop new and innovative treatments for diseases such as stroke, Alzheimer's disease, and multiple sclerosis, researchers have to find ways to overcome the blood-brain barrier," said Lester Drewes, Ph.D., professor of biochemistry and molecular biology at the University of Minnesota Medical School, Duluth campus. "The review has resulted in a number of recommendations to establish and fund research centers that will focus on overcoming these barriers." Drewes is the founding president of the International Brain Barriers Society, a forum for scientists to share their research and fast track discoveries related to the blood-brain barrier. He and 14 other scientists wrote the review.
Edward Neuwelt, M.D., a professor of neurology and neurological surgery in the OHSU School of Medicine and a physician at the Portland Veterans Affairs Medical Center, is among the most active scientists in the international community studying the blood-brain barrier. Neuwelt also was a major participant in the review.
"The blood-brain barrier is the Achille's heel for treating virtually all neurological disorders," said Neuwelt, director of OHSU's Blood-Brain Barrier Program. "However, like the Great Wall of China, there are portals in the barrier that, with proper research, offer a way through." Neuwelt studies ways to open the blood-brain barrier. Other investigators are studying a Trojan horse approach in which therapeutic agents are attached to parts of proteins, such as insulin, that normally cross the barrier.
The researchers examined six topic areas surrounding brain barriers that need to be addressed in order to advance scientific understanding and ultimately improve patient care: Inflammation, injury, tumors, neurodegeneration, specialized barriers, and delivery.
When the brain is injured, as in the case of a stroke, the blood-brain barrier is altered near the site of injury. Changes in the barrier have an effect on how the injury progresses and how much neural tissue is damaged. The researchers suggest that better imaging techniques must be developed to better view the barrier near the injury site.
Improved imaging will also help in furthering research into the effect of brain barriers on tumors. Current imaging techniques do not accurately show the tumor's size, location, type, and response to therapy.
In the study of neurodegenerative diseases, such as Parkinson's, the researchers said often brain barrier is overlooked or only viewed as a barrier to drug delivery. The article suggests that brain barriers play a larger role in the progression of degenerative disease, and that researchers should focus on how the changes in the barriers relate to brain degeneration during the aging process.
In addition to the blood-brain barrier, there are other more specialized barriers in the brain that function in different ways. The scientists suggest that more research needs to be done on how these barriers act alone and in concert with other barriers. Currently there are only limited experimental models of these specialized barriers, and thus little is understood about how they function.
Drug delivery to the brain is extremely complicated. Researchers estimate that very little of therapeutic drugs make it beyond the blood-brain barrier and because of this, progress developing therapies for brain disease is very slow.
The researchers suggest more interdisciplinary research into drug delivery options that would bring together biologists, pharmaceutical scientists, and bioengineers.
University of Minnesota
Many neurological disorders are difficult to treat because of a natural barrier in the brain. The blood-brain barrier is a specialized system of cells that acts as a gatekeeper for the brain, blocking harmful substances from entering while allowing in necessary nutrients. The barrier is necessary to keep the brain and nervous system healthy. However, it also causes problems in medication delivery because it treats medications as the enemy, preventing the therapeutic agents from doing their job.
"In order to develop new and innovative treatments for diseases such as stroke, Alzheimer's disease, and multiple sclerosis, researchers have to find ways to overcome the blood-brain barrier," said Lester Drewes, Ph.D., professor of biochemistry and molecular biology at the University of Minnesota Medical School, Duluth campus. "The review has resulted in a number of recommendations to establish and fund research centers that will focus on overcoming these barriers." Drewes is the founding president of the International Brain Barriers Society, a forum for scientists to share their research and fast track discoveries related to the blood-brain barrier. He and 14 other scientists wrote the review.
Edward Neuwelt, M.D., a professor of neurology and neurological surgery in the OHSU School of Medicine and a physician at the Portland Veterans Affairs Medical Center, is among the most active scientists in the international community studying the blood-brain barrier. Neuwelt also was a major participant in the review.
"The blood-brain barrier is the Achille's heel for treating virtually all neurological disorders," said Neuwelt, director of OHSU's Blood-Brain Barrier Program. "However, like the Great Wall of China, there are portals in the barrier that, with proper research, offer a way through." Neuwelt studies ways to open the blood-brain barrier. Other investigators are studying a Trojan horse approach in which therapeutic agents are attached to parts of proteins, such as insulin, that normally cross the barrier.
The researchers examined six topic areas surrounding brain barriers that need to be addressed in order to advance scientific understanding and ultimately improve patient care: Inflammation, injury, tumors, neurodegeneration, specialized barriers, and delivery.
When the brain is injured, as in the case of a stroke, the blood-brain barrier is altered near the site of injury. Changes in the barrier have an effect on how the injury progresses and how much neural tissue is damaged. The researchers suggest that better imaging techniques must be developed to better view the barrier near the injury site.
Improved imaging will also help in furthering research into the effect of brain barriers on tumors. Current imaging techniques do not accurately show the tumor's size, location, type, and response to therapy.
In the study of neurodegenerative diseases, such as Parkinson's, the researchers said often brain barrier is overlooked or only viewed as a barrier to drug delivery. The article suggests that brain barriers play a larger role in the progression of degenerative disease, and that researchers should focus on how the changes in the barriers relate to brain degeneration during the aging process.
In addition to the blood-brain barrier, there are other more specialized barriers in the brain that function in different ways. The scientists suggest that more research needs to be done on how these barriers act alone and in concert with other barriers. Currently there are only limited experimental models of these specialized barriers, and thus little is understood about how they function.
Drug delivery to the brain is extremely complicated. Researchers estimate that very little of therapeutic drugs make it beyond the blood-brain barrier and because of this, progress developing therapies for brain disease is very slow.
The researchers suggest more interdisciplinary research into drug delivery options that would bring together biologists, pharmaceutical scientists, and bioengineers.
University of Minnesota
Blood-brain Barrier Current Events and Blood-brain Barrier News RSSHormone shows promise in reversing Alzheimer's disease and stroke
Saint Louis University researchers have identified a novel way of getting a potential treatment for Alzheimer's disease and stroke into the brain where it can do its work.
Building the blood-brain barrier
Construction of the brain's border fence is supervised by Wnt/b-catenin signaling, report Liebner et al. in The Journal of Cell Biology.
Phase IIb data show that BG-12 significantly reduced brain lesions in multiple sclerosis
Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p<0.0001).
Clue to genetic cause of fatal birth defect
A novel enzyme may play a major role in anencephaly, offering hope for a genetic test or even therapy for the rare fatal birth defect in which the brain fails to develop, according to a study from researchers at the University of Illinois at Chicago College of Medicine.
Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors.
Ionophore reverses Alzheimer's within days in mouse models
Scientists report a remarkable improvement in Alzheimer's transgenic mice following treatment with a new drug. The study, published by Cell Press in the July 10th issue of the journal Neuron, provides the first demonstration that an ionophore, a compound that transports metal ions across cell membranes, can elicit rapid and pronounced improvement in neuropathology and cognitive function in mouse models of Alzheimer's Disease (AD).
New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.
Leukemia drug could save lives of stroke patients
The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms.
Stroke study reveals key target for improving treatment and suggests that Gleevec may help
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
Chemotherapy causes delayed severe neural damage
Cancer treatment with chemotherapeutic agents is often associated with delayed adverse neurological consequences - an occurrence often referred to as "chemobrain" - that may compromise the quality of life of a proportion of cancer survivors.
More Blood-brain Barrier Current Events and Blood-brain Barrier News Articles
 | Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology Knowledge of the blood-brain barrier forms an essential component in the understanding of a large proportion of medical disciplines. Nevertheless, ignorance in this field still impedes progress in many areas, including cerebrovascular disease, Alzheimer's disease, cerebral AIDS, brain tumors, and the development of effective new neuropharmaceuticals. This introduction for both researchers and... |
 | Blood-Brain Barriers: From Ontogeny to Artificial Interfaces(2 volume set) This first handbook to integrate developmental and cellular aspects combines the different structural and functional features involved in the regulation of brain perfusion and neuronal function. It highlights pharmacological and biomedical applications with sections on drug delivery and disease-related states as well as explaining in detail the role of astrocytes, shown to be an essential link... |
 | Blood'Brain Barrier: Biology and Research Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) Univ. of Toronto, Canada. Text provides the details of selected morphologic, permeability, transport, in vitro, and molecular techniques for BBB studies. Each part is preceded by a review emphasizing the advantages and pitfalls of particular techniques. Written for researchers in BBB. DNLM: Blood--Brain... |
 | The Blood-Brain Barrier and Its Microenvironment: Basic Physiology to Neurological Disease This reference analyzes the cellular and molecular biology and mechanisms of the blood-brain barrier (BBB) and presents the most recent studies on the role of the BBB in the development and initiation of a wide range of physiological and pathological conditions affecting the central nervous... |
 | Blood-Brain Barrier Permeability Changes after Subarachnoid Haemorrhage: An Update: Clinical Implications, Experimental Findings, Challenges and Future Directions by Antonio F. Germano, Francesco Tomasello Univ. of Messina, Italy. Monograph giving an overview of blood-brain barrier permeability after subachnoid hemorrhage, reviewing the subject from both a clinical and basic science perspective. Discusses the historical basis, anatomical substrates, the occurrence, and adverse consequences of barrier disruption of this type. DNLM: Blood-Brain... |
 | The Blood Brain Barrier The blood-brain barrier (BBB) is a membranic structure that acts primarily to protect the brain from chemicals in the blood, while still allowing essential metabolic function. It is composed of endothelial cells, which are packed very tightly in brain capillaries. This higher density restricts passage of substances from the bloodstream much more than endothelial cells in capillaries elsewhere in... |
 | Efflux Transporters and the Blood-Brain Barrier The blood-brain barrier (BBB) creates and maintains the highly regulated extracellular environment of the CNS through three 'lines of defense': a physical barrier formed by tight junctions between endothelial cells of the brain capillaries and epithelial cells of both the choroid plexus and the arachnoid membrane; transporters that mediate the efflux of compounds from brain to blood; and an... |
 | Drug Transport Across the Blood-brain Barrier: In vitro and In vivo Techniques The availability of various in vitro and in vivo techniques has considerably advanced the research on drug transport and metabolism across the blood-brain barrier (BBB). These specialized and sophisticated experimental strategies are of fundamental importance in gaining a greater understanding of enhanced and selective drug delivery to the brain.To aid the study of drug transport across the BBB,... |
 | Blood Brain Barrier: Drug Delivery and Brain Pathology These proceedings review and discuss the different aspects of the biology of the Blood-Brain Barrier (BBB) and its involvement in the pathogenesis of brain disorders.The BBB, formed by a complex cellular system of endothelial cells, astroglia, pericytes, perivascular macrophages and a basal membrane, serves as a controlled functional gate to CNS. In vitro and in vivo models have been established... |
| Implications of the Blood-Brain Barrier and Its Manipulation Volume 2: Clinical Aspects |
| © 2008 BrightSurf.com |